论文部分内容阅读
目的 探讨重组腺病毒p53(Ad p53)与增殖细胞核抗原反义寡核苷酸 (PCNA ASO)联合应用对膀胱癌的抑瘤效应。方法 用腺病毒将p53 [感染强度 (MOI) 1 0 0 ]导入细胞 ,PCNA ASO(1 .6μmol/L)在脂质体 (Lipofectin)介导下转染细胞 ,通过噻唑蓝比色法 (MTT)、流式细胞术、克隆形成、建立移植瘤模型 ,探讨其体内外抗瘤活性。结果 Ad p53与PCNA ASO联合应用明显抑制膀胱癌胞EJ(89.3 % )和BIU 87(78.6 % )生长 ,细胞克隆形成能力分别下降 74.8%和 67.5 % ,S期比率 (EJ细胞 1 1 .4% ,BIU 87细胞 1 4 .6 % )明显降低 ,细胞生长受阻于G1 期 (EJ细胞 62 .2 % ,BIU 87细胞 56 .8% ) ;联合应用 7d后 ,肿瘤体积较初始分别下降 47.6 %和 36 .4%。结论 Ad p53联合PCNA ASO可抑制膀胱癌细胞体内外生长 ,产生协同效应
Objective To investigate the antitumor effect of recombinant adenovirus p53 (Ad p53) combined with proliferating cell nuclear antigen antisense oligonucleotide (PCNA ASO) on bladder cancer. Methods Adenovirus was used to transduce p53 [infection intensity (MOI) 1 0 0] into cells. PCNA ASO (1. 6 μmol / L) was transfected into the cells under lipofectin. MTT ), Flow cytometry, cloning, the establishment of xenograft model to explore its in vitro and in vivo anti-tumor activity. Results The combination of Ad p53 and PCNA ASO significantly inhibited the growth of bladder cancer cells EJ (89.3%) and BIU 87 (78.6%). The cell clonogenic capacity decreased by 74.8% and 67.5%, respectively. The S phase ratio (EJ cells 11.4% , BIU 87 cells (14.6%) decreased significantly, and cell growth was blocked in G1 phase (62.2% in EJ cells and 56.8% in BIU 87 cells); after 7 days of combination, the tumor volume decreased by 47.6% 36.4%. Conclusions Ad p53 combined with PCNA ASO can inhibit the growth of bladder cancer cells in vitro and in vivo, resulting in a synergistic effect